TCGA-22-1002-01A-01R-A96U-41
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.300
- MITOTIC_SPINDLE+0.260
- ANGIOGENESIS+0.180
- TGF_BETA_SIGNALING+0.180
- IL6_JAK_STAT3_SIGNALING+0.140
- TNFA_SIGNALING_VIA_NFKB+0.140
- BILE_ACID_METABOLISM+0.080
- MYOGENESIS+0.080
- G2M_CHECKPOINT+0.070
- HEME_METABOLISM+0.060
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- GLYCOLYSIS-0.330
- MTORC1_SIGNALING-0.290
- ESTROGEN_RESPONSE_LATE-0.280
- PANCREAS_BETA_CELLS-0.260
- UV_RESPONSE_UP-0.250
- OXIDATIVE_PHOSPHORYLATION-0.240
- ALLOGRAFT_REJECTION-0.210
- PEROXISOME-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-22-1016-01A-01R-A96U-41 | — | cohortMD2 | 0.879 |
| 2 | TCGA-AC-A3QQ-01B-06R-A22O-07 | — | D | 0.765 |
| 3 | c874c481-cff8-4e2d-99b1-3b5aeaaecb8e | — | — | 0.725 |
| 4 | TCGA-A7-A26I-01B-06R-A22O-07 | — | D | 0.721 |
| 5 | ba2b0b86-f7f1-47f7-b0fd-bec3f623febb | — | — | 0.708 |
| 6 | ec48e2b8-ca0a-40fe-a87b-f0e955466840 | — | — | 0.705 |
| 7 | 19645f04-0021-4b2d-ad56-b1342c6ca519 | — | — | 0.702 |
| 8 | TCGA-BH-A0B5-01A-11R-A12P-07 | — | A | 0.690 |
| 9 | TCGA-A7-A26J-01B-02R-A277-07 | — | D | 0.689 |
| 10 | TCGA-A7-A26E-01B-06R-A277-07 | — | D | 0.688 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |